A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
about
Trametinib: a MEK inhibitor for management of metastatic melanomaMolecular landscape of pancreatic cancer: implications for current clinical trialsEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.BCL-2 is dispensable for thrombopoiesis and platelet survivalTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporterSelumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.Trametinib: first global approval.Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.Promising new therapies in advanced pancreatic adenocarcinomas.Trametinib in the treatment of melanoma.Allosteric therapies for lung cancer.Ocular toxicities of MEK inhibitors and other targeted therapies.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma.Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
P2860
Q26782976-42F2EEEF-357A-4FDB-8384-9A2BD67702FAQ26824528-1C51C9E5-1210-400D-A9C7-5B6D239FF7D7Q27853021-7691BF17-CEA3-4B89-8E30-9974666D2A19Q30275521-2565B36E-FF52-4811-9327-DDA1A4F6721AQ33422077-F4A7A55F-30A3-4D9B-B674-C09A32304C0DQ33769821-23555EE7-EBF3-4323-A706-898507667F53Q34592684-F5E547E8-8F1C-4981-90CD-DD2F45F47373Q35136815-137A225F-231F-4713-A052-C55FC161D335Q36021057-E06CDA32-4958-460A-85AD-4B66F2D0666CQ36171262-04CA884B-5DBC-4C0F-BDD5-A7BAD64983C4Q36917882-D4A66AC7-471E-4547-B8E5-312A94C93582Q38121015-5082B8C1-5974-4410-A24E-086F4C715FFEQ38199737-B15344DE-24A3-49A8-8306-5C343AF14A2FQ38296663-9F3E990E-0FBC-4962-BAA1-F3041E899D8FQ38392273-9B04BC23-621F-49E4-92AF-3595461BD07DQ38465098-10A8F062-7EF6-41C1-B1BD-AD7BB527EF41Q38764273-41825794-A5AA-4E39-AC33-02FFD3B9BA49Q38799845-5F8A6387-9761-4B10-ABA3-7BD2223EFB55Q41484629-65A29700-6A27-4105-93FC-A701F6A39834Q47871357-7B36773E-8AE6-49DF-A70F-49B95BADC99AQ48611990-16136AAF-6F92-41D8-AC9B-C5303CC20C14Q49887897-9C75D551-3B9C-47BA-BE22-23849FC0CBBAQ53389706-933B834B-71CB-42F3-8EED-4EAD6241F100Q54965602-D7D11A7B-179F-463C-974B-46BC2AB4990E
P2860
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@ast
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@en
type
label
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@ast
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@en
prefLabel
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@ast
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@en
P2093
P1476
A phase 1b study of trametinib ...... ine in advanced solid tumours.
@en
P2093
Amita Patnaik
Anthony W Tolcher
Donna S Cox
Drew Rasco
Howard A Burris
Jeffrey R Infante
Johanna C Bendell
Joohyun Jennifer Park
Kevin M Bellew
Kyriakos P Papadopoulos
P304
P356
10.1016/J.EJCA.2013.03.020
P577
2013-04-11T00:00:00Z